Table 2 Characteristics of patient samples in groups for miR-150 and MYB expression analysis
From: Expression patterns of microRNAs associated with CML phases and their disease related targets
Disease stage | Number of patients | HU, IFN or combination pretreatment months from diagnosis median (range) | Months on imatinib median (range) | WBC x109/L PB median (range) PLT x109/L PB median (range) | Blasts in PB (%) median (range) | Ph+ cells (%) median (range) | BCR-ABL (%) median (range) | BCR-ABL KD mutation Number of patients |
|---|---|---|---|---|---|---|---|---|
Dg | 13 | NA | NA | 67 (22-457) | 2 (1-5) | 100 | 132 (61-312) | NA |
481 (130-824) | ||||||||
AP/BC | 12 | 24 (2-106) | 24 (8-55) | 34 (1.17-147) | 18 (8-76) | 100 | 510 (103-2500) | 3 |
81 (14-562) | ||||||||
Hr | 15 | 18 (1-66) | 22 (10-54) | 16 (6-28) | 10; 12 | 100 (32-100) | 80 (23-827) | 15 |
448 (71-1779) | ||||||||
TF | 14 | 14 (1-68) | 18 (12-67) | Phy | 0 | 100 (40-100) | 32 (11-91) | 4 |
Phy | ||||||||
MMR | 16 | 3 (1-11) | 16 (7-24) | Phy | 0 | 0 | 0.02 (0.001-0.1) | NA |
Phy |